An observational study in Asthma and Allergy, sponsored by AstraZeneca. Completed at 80 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-05.
Sponsored by AstraZeneca · Observational
The aim of the study is to evaluate the efficacy of Alvesco in patients with persistent asthma including or excluding allergic components over 3 months, especially in the spring season. Alvesco will be inhaled by a metered-dose inhaler. The study will provide further data on safety and tolerability of Alvesco .
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's planned enrollment of 400 is above the median of 150 across 970 observational studies indexed under Asthma.
Browse Asthma studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Outpatients
Main Inclusion Criteria:
Main Exclusion Criteria:
A prospective one-arm non-interventional study with asthma patients treated with Alvesco.
Drug: Alvesco
This is an observational study. Therefore, the physician decides about dosage according to individual needs.
Also known as: Ciclesonide
Treatment success with Alvesco
Pre-/ post comparison of FEV1, Quality of life, Patient Questionnaire
Time frame: after 3 months
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time frame: after 3 months
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca